O	0	5	Prone
O	6	12	breast
B-intervention	13	22	intensity
I-intervention	23	32	modulated
I-intervention	33	42	radiation
I-intervention	43	50	therapy
O	50	51	:
O	52	53	5
O	53	54	-
O	54	58	year
O	59	66	results
O	66	67	.

O	68	70	To
O	71	77	report
O	78	81	the
O	82	83	5
O	83	84	-
O	84	88	year
O	89	96	results
O	97	99	of
O	100	101	a
O	102	111	technique
O	112	114	of
O	115	120	prone
O	121	127	breast
O	128	137	radiation
O	138	145	therapy
O	146	155	delivered
O	156	158	by
O	159	160	a
O	161	168	regimen
O	169	171	of
O	172	183	accelerated
O	184	193	intensity
O	194	203	modulated
O	204	213	radiation
O	214	221	therapy
O	222	226	with
O	227	228	a
O	229	239	concurrent
O	240	245	boost
O	246	248	to
O	249	252	the
O	253	258	tumor
O	259	262	bed
O	262	263	.

O	264	271	Between
O	272	276	2003
O	277	280	and
O	281	285	2006
O	285	286	,
B-total-participants	287	290	404
B-eligibility	291	299	patients
I-eligibility	300	304	with
I-eligibility	305	310	stage
I-eligibility	311	312	I
I-eligibility	312	313	-
I-eligibility	313	315	II
I-eligibility	316	322	breast
I-eligibility	323	329	cancer
O	330	334	were
O	335	348	prospectively
O	349	357	enrolled
O	358	362	into
O	363	364	2
O	365	376	consecutive
O	377	386	protocols
O	386	387	,
O	388	401	institutional
O	402	408	trials
O	409	411	03
O	411	412	-
O	412	414	30
O	415	418	and
O	419	421	05
O	421	422	-
O	422	425	181
O	425	426	,
O	427	431	that
O	432	436	used
O	437	440	the
O	441	445	same
O	446	453	regimen
O	454	456	of
O	457	459	40
O	459	460	.
O	460	461	5
O	462	464	Gy
O	464	465	/
O	465	467	15
O	468	477	fractions
O	478	487	delivered
O	488	490	to
O	491	494	the
O	495	500	index
O	501	507	breast
O	508	512	over
O	513	514	3
O	515	520	weeks
O	520	521	,
O	522	526	with
O	527	528	a
O	529	540	concomitant
O	541	546	daily
O	547	552	boost
O	553	555	to
O	556	559	the
O	560	565	tumor
O	566	569	bed
O	570	572	of
O	573	574	0
O	574	575	.
O	575	576	5
O	577	579	Gy
O	580	581	(
O	581	586	total
O	587	591	dose
O	592	594	48
O	595	597	Gy
O	597	598	)
O	598	599	.

O	600	603	All
O	604	612	patients
O	613	617	were
O	618	625	treated
O	626	631	after
O	632	641	segmental
O	642	652	mastectomy
O	653	656	and
O	657	660	had
O	661	669	negative
O	670	677	margins
O	678	681	and
O	682	687	nodal
O	688	698	assessment
O	698	699	.

O	700	708	Patients
O	709	713	were
O	714	717	set
O	718	720	up
O	721	726	prone
O	726	727	:
O	728	732	only
O	733	735	if
O	736	740	lung
O	741	743	or
O	744	749	heart
O	750	757	volumes
O	758	762	were
O	763	765	in
O	766	769	the
O	770	775	field
O	776	779	was
O	780	781	a
O	782	788	supine
O	789	794	setup
O	795	804	attempted
O	805	808	and
O	809	815	chosen
O	816	818	if
O	819	824	found
O	825	827	to
O	828	834	better
O	835	840	spare
O	841	846	these
O	847	853	organs
O	853	854	.

O	855	861	Ninety
O	861	862	-
O	862	865	two
O	866	873	percent
O	874	876	of
O	877	885	patients
O	886	890	were
O	891	898	treated
O	899	904	prone
O	904	905	,
O	906	907	8
O	907	908	%
O	909	915	supine
O	915	916	.

O	917	924	Seventy
O	924	925	-
O	925	928	two
O	929	936	percent
O	937	940	had
O	941	946	stage
O	947	948	I
O	948	949	,
O	950	952	28
O	952	953	%
O	954	959	stage
O	960	962	II
O	963	971	invasive
O	972	978	breast
O	979	985	cancer
O	985	986	.

O	987	989	In
O	989	990	-
O	990	995	field
O	996	1000	lung
O	1001	1007	volume
O	1008	1014	ranged
O	1015	1019	from
O	1020	1021	0
O	1022	1024	to
O	1025	1028	228
O	1028	1029	.
O	1029	1031	27
O	1032	1034	cm
O	1034	1035	(
O	1035	1036	3
O	1036	1037	)
O	1037	1038	,
O	1039	1043	mean
O	1044	1046	19
O	1046	1047	.
O	1047	1049	65
O	1050	1052	cm
O	1052	1053	(
O	1053	1054	3
O	1054	1055	)
O	1055	1056	.

O	1057	1059	In
O	1059	1060	-
O	1060	1065	field
O	1066	1071	heart
O	1072	1078	volume
O	1079	1082	for
O	1083	1087	left
O	1088	1094	breast
O	1095	1101	cancer
O	1102	1110	patients
O	1111	1117	ranged
O	1118	1122	from
O	1123	1124	0
O	1125	1127	to
O	1128	1130	21
O	1130	1131	.
O	1131	1133	24
O	1134	1136	cm
O	1136	1137	(
O	1137	1138	3
O	1138	1139	)
O	1139	1140	,
O	1141	1145	mean
O	1146	1147	1
O	1147	1148	.
O	1148	1150	59
O	1151	1153	cm
O	1153	1154	(
O	1154	1155	3
O	1155	1156	)
O	1156	1157	.

O	1158	1163	There
O	1164	1167	was
O	1168	1170	no
O	1171	1176	heart
O	1177	1179	in
O	1180	1183	the
O	1184	1189	field
O	1190	1193	for
O	1194	1199	right
O	1200	1206	breast
O	1207	1213	cancer
O	1214	1222	patients
O	1222	1223	.

O	1224	1226	At
O	1227	1228	a
O	1229	1235	median
O	1236	1242	follow
O	1242	1243	-
O	1243	1245	up
O	1246	1248	of
O	1249	1250	5
O	1251	1256	years
O	1256	1257	,
O	1258	1261	the
B-outcome	1262	1263	5
I-outcome	1263	1264	-
I-outcome	1264	1268	year
I-outcome	1269	1279	cumulative
I-outcome	1280	1289	incidence
I-outcome	1290	1292	of
I-outcome	1293	1301	isolated
I-outcome	1302	1313	ipsilateral
I-outcome	1314	1320	breast
I-outcome	1321	1326	tumor
I-outcome	1327	1337	recurrence
O	1338	1341	was
B-iv-bin-percent	1342	1343	0
I-iv-bin-percent	1343	1344	.
I-iv-bin-percent	1344	1346	82
I-iv-bin-percent	1346	1347	%
O	1348	1349	(
O	1349	1351	95
O	1351	1352	%
O	1353	1363	confidence
O	1364	1372	interval
O	1373	1374	[
O	1374	1376	CI
O	1376	1377	]
O	1378	1379	0
O	1379	1380	.
O	1380	1382	65
O	1382	1383	%
O	1383	1384	-
O	1384	1385	1
O	1385	1386	.
O	1386	1388	04
O	1388	1389	%
O	1389	1390	)
O	1390	1391	.

O	1392	1395	The
B-outcome	1396	1397	5
I-outcome	1397	1398	-
I-outcome	1398	1402	year
I-outcome	1403	1413	cumulative
I-outcome	1414	1423	incidence
I-outcome	1424	1426	of
I-outcome	1427	1435	regional
I-outcome	1436	1446	recurrence
O	1447	1450	was
B-iv-bin-percent	1451	1452	0
I-iv-bin-percent	1452	1453	.
I-iv-bin-percent	1453	1455	53
I-iv-bin-percent	1455	1456	%
O	1457	1458	(
O	1458	1460	95
O	1460	1461	%
O	1462	1464	CI
O	1465	1466	0
O	1466	1467	.
O	1467	1469	41
O	1469	1470	%
O	1470	1471	-
O	1471	1472	0
O	1472	1473	.
O	1473	1475	69
O	1475	1476	%
O	1476	1477	)
O	1477	1478	,
O	1479	1482	and
O	1483	1486	the
B-outcome	1487	1488	5
I-outcome	1488	1489	-
I-outcome	1489	1493	year
I-outcome	1494	1501	overall
I-outcome	1502	1512	cumulative
I-outcome	1513	1518	death
I-outcome	1519	1523	rate
O	1524	1527	was
B-iv-bin-percent	1528	1529	1
I-iv-bin-percent	1529	1530	.
I-iv-bin-percent	1530	1532	28
I-iv-bin-percent	1532	1533	%
O	1534	1535	(
O	1535	1537	95
O	1537	1538	%
O	1539	1541	CI
O	1542	1543	0
O	1543	1544	.
O	1544	1546	48
O	1546	1547	%
O	1547	1548	-
O	1548	1549	3
O	1549	1550	.
O	1550	1552	38
O	1552	1553	%
O	1553	1554	)
O	1554	1555	.

B-iv-bin-percent	1556	1562	Eighty
I-iv-bin-percent	1562	1563	-
I-iv-bin-percent	1563	1566	two
I-iv-bin-percent	1567	1574	percent
O	1575	1576	(
O	1576	1578	95
O	1578	1579	%
O	1580	1582	CI
O	1583	1585	77
O	1585	1586	%
O	1586	1587	-
O	1587	1589	85
O	1589	1590	%
O	1590	1591	)
O	1592	1594	of
O	1595	1603	patients
B-outcome	1604	1610	judged
I-outcome	1611	1616	their
I-outcome	1617	1622	final
I-outcome	1623	1631	cosmetic
I-outcome	1632	1638	result
I-outcome	1639	1641	as
I-outcome	1642	1651	excellent
I-outcome	1651	1652	/
I-outcome	1652	1656	good
O	1656	1657	.

O	1658	1663	Prone
O	1664	1675	accelerated
O	1676	1685	intensity
O	1686	1695	modulated
O	1696	1705	radiation
O	1706	1713	therapy
O	1714	1718	with
O	1719	1720	a
O	1721	1732	concomitant
O	1733	1738	boost
O	1739	1746	results
O	1747	1749	in
O	1750	1759	excellent
O	1760	1765	local
O	1766	1773	control
O	1774	1777	and
O	1778	1785	optimal
O	1786	1793	sparing
O	1794	1796	of
O	1797	1802	heart
O	1803	1806	and
O	1807	1811	lung
O	1811	1812	,
O	1813	1817	with
O	1818	1822	good
O	1823	1831	cosmesis
O	1831	1832	.

O	1833	1842	Radiation
O	1843	1850	Therapy
O	1851	1859	Oncology
O	1860	1865	Group
O	1866	1874	protocol
O	1875	1879	1005
O	1879	1880	,
O	1881	1882	a
O	1883	1888	phase
O	1889	1890	3
O	1890	1891	,
O	1892	1897	multi
O	1897	1898	-
O	1898	1911	institutional
O	1911	1912	,
O	1913	1923	randomized
O	1924	1929	trial
O	1930	1932	is
O	1933	1940	ongoing
O	1941	1944	and
O	1945	1947	is
O	1948	1958	evaluating
O	1959	1962	the
O	1963	1974	equivalence
O	1975	1977	of
O	1978	1979	a
O	1980	1987	similar
O	1988	1992	dose
O	1993	1996	and
O	1997	2010	fractionation
O	2011	2019	approach
O	2020	2022	to
O	2023	2031	standard
O	2032	2033	6
O	2033	2034	-
O	2034	2038	week
O	2039	2048	radiation
O	2049	2056	therapy
O	2057	2061	with
O	2062	2063	a
O	2064	2074	sequential
O	2075	2080	boost
O	2080	2081	.
